Alberta – Access to Treatments

Province of Alberta

Access to Treatments

Accessing tyrosine kinase inhibitors (TKIs) for Chronic Myeloid Leukemia (CML) varies across Canadian provinces. Below is a step-by-step guide for patients in Alberta.

Alberta:

Consultation: Meet with your oncologist to evaluate TKI treatment options.
Prescription: Your doctor will prescribe the suitable TKI based on your condition.
Coverage: Alberta Health Services provides coverage for certain TKIs through the Outpatient Cancer Drug Benefit Program. Verify the inclusion of your prescribed TKI.

Application: If required, your healthcare provider will assist in the application process.
Approval: After approval, the medication can be obtained from specified pharmacies.

Drugs approved for treatment of CML at the Alberta Cancer Agency:
Scemblix (Ascinimib), Bosulif (Bosutinib), Sprycel (Dasatinib), Gleevec (Imatinib), Tasigna (Nilotinib), Iclusig (Ponatinib).

Province of Alberta

Access to Treatments

Accessing tyrosine kinase inhibitors (TKIs) for Chronic Myeloid Leukemia (CML) varies across Canadian provinces. Below is a step-by-step guide for patients in Alberta.

Alberta

Consultation: Meet with your oncologist to evaluate TKI treatment options.

Prescription: Your doctor will prescribe the suitable TKI based on your condition.

Coverage: Alberta Health Services provides coverage for certain TKIs through the Outpatient Cancer Drug Benefit Program. Verify the inclusion of your prescribed TKI.

Application: If required, your healthcare provider will assist in the application process.

Approval: After approval, the medication can be obtained from specified pharmacies.

Drugs approved for treatment of CML at the Alberta Cancer Agency:

Scemblix (Ascinimib), Bosulif (Bosutinib), Sprycel (Dasatinib), Gleevec (Imatinib), Tasigna (Nilotinib), Iclusig (Ponatinib).